Filing summary
Entity note: The supplied filing is Celsion Corporation’s Form 10-Q, not a filing identified as Imunon, Inc. It covers the quarter ended September 30, 2011, and the nine months then ended.
Business context and results
Celsion was a clinical-stage oncology drug developer focused on heat-activated liposomal therapies. Its lead candidate, ThermoDox, was in a Phase III trial for primary liver cancer and a Phase I/II trial for recurrent chest-wall breast cancer. The company reported no product sales.
| Metric | Three months ended Sep. 30, 2011 | Nine months ended Sep. 30, 2011 | Prior-year comparison |
|---|---|---|---|
| Revenue | None | $2.0 million licensing revenue | None in 2010; nine-month revenue was Yakult-related |
| Operating expenses | $6.82 million | $18.63 million | Up 31.9% and 31.1%, respectively |
| Net loss | $6.39 million | $17.10 million | $4.72 million and $13.49 million in 2010 |
| Basic and diluted loss per share | $0.25 | $0.93 | $0.38 and $1.10 in 2010 |
| Net cash used in operations | Not separately stated | $18.30 million | $10.60 million in the first nine months of 2010 |
| Cash and short-term investments | $21.41 million at Sep. 30, 2011 | $1.53 million at Dec. 31, 2010 |
Quarterly R&D expense rose 37% to $5.41 million, primarily with higher Phase III HEAT trial enrollment and manufacturing-development costs. Nine-month R&D expense increased 38% to $14.73 million. G&A rose 15.5% for the quarter and 10.2% for the nine-month period. Profit margins are not meaningful given the absence of recurring product revenue and ongoing development spending.
Financial position and changes
- Current assets were $22.21 million and current liabilities $4.64 million, for working capital of $17.58 million; this compared with a $4.77 million working-capital deficit at year-end 2010.
- Cash was $11.13 million, with $10.28 million in short-term investments. Total liabilities were $4.93 million, including $88,799 of current note payable and a $290,613 warrant liability. The filing reports no non-current note payable at quarter-end.
- Financing activities generated $38.90 million of net cash in the first nine months, chiefly from equity offerings. Management reported approximately $40 million of net equity proceeds from 2011 financings. The offerings materially increased shares outstanding and included warrants; the CEFF was exhausted in the second quarter.
- The $2 million Yakult licensing revenue recognized in the first quarter followed an amendment accelerating a portion of a future approval milestone. In exchange, future ThermoDox approval milestone payments were reduced by approximately 40% if the contemplated accelerated payments are made.
Outlook, risks and notable items
- Management said available cash was expected to fund operations for the next 12 months, but also stated that additional capital would be required in 2012. It gave no specific revenue, earnings or spending guidance.
- The HEAT Phase III trial reached its 600-patient enrollment objective in August 2011 and reached 190 progression-free-survival events in the third quarter, enabling a planned interim analysis in the fourth quarter of 2011. The filing cautions that the analysis could fail or be delayed.
- In July, the trial’s data monitoring committee recommended continued enrollment outside Japan while withholding additional enrollment in Japan pending guidance from Japan’s PMDA. Resumption was uncertain; the additional $2 million Yakult payment was conditional on resumption of Japanese enrollment.
- Key risks include clinical or regulatory failure, uncertain development timing and costs, dependence on ThermoDox, and the need for further financing. Additional equity could dilute shareholders; debt or partnership arrangements could impose senior claims or require concessions of rights.
- The company relocated its offices in October 2011 under a 66-month lease, with six months rent-free and monthly rent of approximately $23,000 beginning in April 2012. It secured a $250,000 letter of credit with a matching bank deposit.
Important facts for investors to verify
- Whether the planned HEAT interim analysis occurred and what the results and regulatory implications were.
- Whether Japanese enrollment resumed and whether the conditional Yakult payment was received.
- Actual cash runway and subsequent financing needs, considering the reported $18.30 million nine-month operating cash use.
- The full dilution and potential proceeds associated with the 2011 share issuances and outstanding warrants.
- Whether later filings clarify the company identity relevant to the request, since this source names Celsion Corporation.